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Abstract
Burrowing, an ethologically relevant rodent behaviour, has been proposed as a novel outcomemeasure to assess the global impact of
pain in rats. In a prospectivemulticentre study usingmale rats (Wistar, Sprague-Dawley), replication of suppressed burrowing behaviour
in the complete Freund adjuvant (CFA)-inducedmodel of inflammatory pain (unilateral, 1 mg/mL in 100 mL) was evaluated in 11 studies
across 8 centres. Following a standard protocol, data from participating centres were collected centrally and analysed with a restricted
maximum likelihood-basedmixedmodel for repeated measures. The total population (TP—all animals allocated to treatment; n5 249)
anda selectedpopulation (SP—TPanimals burrowing over 500 g at baseline; n5 200)were analysed separately, assessing the effect of
excluding “poor” burrowers. Mean baseline burrowing across studies was 1113 g (95% confidence interval: 1041-1185 g) for TP and
1329 g (1271-1387 g) for SP. Burrowing was significantly suppressed in the majority of studies 24 hours (7 studies/population) and 48
hours (7 TP, 6 SP) afterCFA injections. Across all centres, significantly suppressed burrowing peaked 24 hours after CFA injections,with
a burrowing deficit of 2374 g (2479 to 2269 g) for TP and 2498 g (2609 to 2386 g) for SP. This unique multicentre approach first
provided high-quality evidence evaluating suppressedburrowing as robust and reproducible, supporting its use as tool to infer theglobal
effect of pain on rodents. Second, our approach provided important informative value for the use of multicentre studies in the future.
Keywords: Non-evoked pain, Validation, Reproducibility, Preclinical controlled trials
1. Introduction
Prospective multicentre controlled trials are an important clinical
research tool, providing high-quality evidence to inform health
care systems about the validity of new treatments and outcome
measures. In contrast, preclinical studies are predominantly
single-centre studies conducted using experimental protocols
varying significantly across laboratories. This likely contributes to
the well-recognized poor level of experimental reproducibility.54
Implementing the concept, ethos, and design of multicentre
clinical trials into preclinical studies could significantly increase
reproducibility and translatability by standardising experimental
design, monitoring data, and improving reporting standards.
The use of multicentre designs in preclinical studies is rare;
however, a few pioneering studies in mice have demonstrated the
effects of environmental conditions, strain, and study design on
behavioural outcomesacrosscentres.37,40,59Amulticentre approach
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for preclinical pain studies could equally provide robust validation and
evidence for reproducibility of models, outcome measures, and
pharmacological interventions. This could be achieved by system-
atically assessing replication and interlaboratory variability and
identifying factors that may be associated with such variability.
A major shortcoming in chronic pain research has been the lack
of newly developed analgesics, because translation from promising
preclinical studies to successful clinic trials has been poor.49,65,75
Animal studiesmostly rely on stimulus-evokedmeasures of sensory
gain, whereas clinical trials use patient-reported outcomes focusing
on spontaneous pain intensity, functioning, and quality of life.
Although spontaneous pain and decreased quality of life are
reported across chronic pain conditions,11,16,52,56 sensory gain is
common only in a subset of clinical pain conditions caused by
peripheral nerve trauma and inflammation but is rare in others, such
as polyneuropathies caused by diabetes and HIV.39,51,52,56 This
has brought into question the translational strength of relying on
sensory gain as the sole pain outcome measure preclinically.3,48,57
We have previously proposed ethologically relevant rodent
behaviours, such as predator avoidance behaviours, as novel
nonevoked pain outcomemeasures to assess the global impact of
pain on animals.10,23,25,60,72–74
Among these ethologically relevant behaviours is burrowing.
Burrowing, a social behaviour of rats that is important for building
underground habitats and nests, is highly conserved in laboratory
rats.5 Suppressed burrowing, quantified by a reduced amount of
displaced substrate from an artificial burrow, is indicative of
behavioural dysfunction.14 Pain-depressed behaviours, such as
reduction in feeding, locomotion, or operant behaviours, have been
proposed as pain-relevant measures that assess functioning instead
of sensory changes.45 Although burrowing is a relatively novel pain
outcomemeasure, a fewstudieshave reporteddecreasedburrowing
in rat models of inflammatory and neuropathic pain; importantly,
burrowing deficits were reversed by known analgesics, suggesting
a degree of predictive validity for this outcome measure.2,9,20,35,61,62
We hypothesise that by using a prospective multicentre design,
the reliability of novel outcome measures can be efficiently and
rapidly evaluated. As part of the IMI Europain collaboration (http://
www.imieuropain.org), we investigated rat burrowing behaviour
after induction of complete Freund adjuvant (CFA)-associated
inflammation across 8 centres to assess the reliability of suppressed
burrowing as a pain-related outcome measure. We hope this will
facilitate future routine use of multicentre studies to evaluate novel
outcome measures and models.
2. Materials and methods
The purpose of this study was to identify whether the impact of
CFA-induced inflammation on burrowing behaviour can be
reproduced acrossmultiple centreswhen following abasic protocol
(Supplemental digital content 1, http://links.lww.com/PAIN/A302).
For this, a draft protocol was written and then reviewed by the
participating centres before it was finalised. Minor changes to the
protocol were permitted to accommodate for local variations in
laboratory practice and procedures (eg, different animal suppliers,
variations in environmental conditions, substrate and equipment
availability, and precise randomisation procedures).
2.1. Ethical statement
All animal experiments conformed to local Government and
Institutional guidelines on the care and use of animals in research
and the IASP guidelines for in vivo research.26,76 Guidance was
given on Good Laboratory Practice standards,38,58 but exact
methods were not specified, and local variations were allowed
and recorded (Table 1). Experiments are reported in accordance
with the ARRIVE Guidelines32 (Supplemental digital content 6,
http://links.lww.com/PAIN/A307).
2.2. Experimental animals and environmental conditions
Adult male rats were used for all experiments. Animals were
group-housed in standard cages in temperature and humidity-
controlled conditions (Table 1). Bedding and environmental
enrichment was provided according to local convention, in-
cluding nesting material, jolly balls, or cardboard/plastic tubes.
Animals were provided with standard rat chow pellets and tap
water ad libitum and were allowed to acclimatise to their housing
environment for a minimum of 4 to 7 days before experiments
started. Animals were monitored during regular husbandry
activity to ensure their well-being.
2.3. Complete Freund’s adjuvant—induced inflammation
Inflammation was induced under isoflurane/O2 anaesthesia by
unilateral intraplantar injection of CFA. Sham animals received
a saline or incomplete CFA injection of the same volume. TheCFA
model was chosen because of the high likelihood of ongoing
spontaneous pain, as reported in humans after an accidental CFA
injection19 and in animals.46,47
2.4. Burrowing
Burrowing experiments were performed as previously de-
scribed.2,62 For this, a burrowing tube (320 3 100 mm; open end
elevated by 60 mm), made of either steel (Boehringer Ingelheim) or
plastic (all other groups), was filledwith 2500g substrate andplaced
in an empty cage (Fig. 1). No floor bedding was provided during the
burrowing task, as this could hinder cleaning of the substrate. In
some studies, however, the cage floor was covered with paper
towels to create a more comfortable environment for the animals. If
multiple animal cohorts were tested per day, test cages were
emptied of displaced substrate, faecal boli and tissue paper, and
were wiped clean or replaced with a clean testing cage before
starting the next session. As free access to food and water could
distract animals from burrowing, most studies opted not to provide
food and water during testing. At studies performed at Eli Lilly
(United Kingdom), water was accessible during testing, as local
regulations only allowed amaximal period of 2 hours without water.
Details of the experimental set-ups can be found in Table 2.
2.4.1. Training—social facilitation
For animals to learn the task, 2 to 3 training sessions were
conducted over consecutive days (apart from weekends). After
acclimatisation to the testing room and/or experimental set-up
without a burrowing tube, a filled burrowing tube was placed in the
test cage, and animals, in pairs, were allowed to burrow for 60 to
120 minutes. If a pair showed poor burrowing behaviour during the
first training session, one of the animals was swapped with an
animal from a known burrowing pair to facilitate burrowing in
subsequent sessions. As no criterion was set a priori to define
a poor burrowing pair, experimenters determined this on a case-by-
case basis. At Boehringer Ingelheim, pairs burrowing less than
1500 g were classified as poor burrowers; because strong
burrowers would displace nearly all of the 2500 g substrate, this
high limit was set to ensure the behaviour was strongly expressed.
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Table 1
Major domains of Good Laboratory Practice.
Description of the procedure
Boehringer Ingelheim
Pharma GmbH
Gru¨nenthal
GmbH
Heidelberg University Asahi Kasei Pharma University of
Manchester
Eli Lilly and Company
(United Kingdom)
Imperial College
London
Eli Lilly and Company
(USA)
Animals Animal characteristics for each study can be found in Table 3 and in the results in “3.1 Study profile, animal characteristics, and experimental design.” Details about species, strain, sex, weight, and supplier are given
Housing
environment/
experimental lighting
conditions
20-22˚C;
45%-60% humidity; 12/
12 h light/dark cycle/
lights
15 lux
19-23˚C; 15%-50%
humidity; 12/12 h light/
dark cycle/dimmed lights
23-24˚C; 47%-63%
humidity; 13/11 h light/
dark cycle/lights 0.8-7.6
lux
24-26˚C;
49%-66% humidity; 12/
12 h light/dark cycle/
dimmed lights (,50 lux)
19-21˚C; 50% humidity;
12/12 h light/dark cycle/
lights 30-60 lux
20-22˚C;
30%-70% humidity; 12/
12 h light/dark cycle/
bright lights (study 1 and
2); dimmed lights (study
3)
23˚C; 35%-40% humidity;
12/12 h light/dark cycle/
lights
30-60 lux
23˚C; 35%-40% humidity;
12/12 h light/dark cycle/
lights
30-60 lux
Sample size Sample size estimation (SigmaPlot 11.0 [analysis of variance]) was calculated with pilot burrowing data at 3 d after induction of inflammation (n5 6 and n5 5 for control and complete Freund adjuvant groups, respectively).
Parameters were difference in means5 951.79 g, SD5 549.29 g,a5 0.05, and power5 0.8. An adequately powered study required an n5 7 per group and n5 8 when testing 2 and 3 groups, respectively. N numbers
for each study are reported in the results and in Figure 2
Inclusion/exclusion
criteria
In the basic protocol, animals that burrowed more or less than 2 SD of the total mean at baseline sessions should have been excluded before model induction. However, because of high variability, this never occurred.
Alternative criteria were discussed including the exclusion of animals that burrowed less than 500g at baseline. Thus, at Eli Lilly (United Kingdom), 5 of 32 animals in study 1 and at Gru¨nenthal 1 of 22 animals were excluded
before model induction as they burrowed less than 500 g during baseline measurements. No data from these animals was included. At Boehringer Ingelheim, rats were excluded when burrowing on average,1000 g or had
an SD.450 g after 3 individual training days; no animals had to be excluded according to this criterion. For all other studies investigators opted to not exclude animals before model induction but instead analyse burrowing
behaviour with a total population and selected population approach as described below. Exclusions are reported in Figure 2
Randomisation to
groups: naive, sham,
CFA or sham, CFA
Animals were randomly
allocated to groups by
using a random number
generator in Excel.
Baseline values (mean 3
baseline sessions) were
then used to shift
individual values, in
a blinded fashion, from
group to group until each
group had a comparable
baseline in terms of
mean value and variation
Baseline values were
ranked from low to high
performers and
pseudorandomised by
allocating them to groups
following a repeated
sequence. Individual
values were shifted from
group to group until each
group had a comparable
baseline in terms of
mean value and variation
Baseline values were
used to rank animals
from low to high
performers and
pseudorandomised by
allocating them to groups
in an alternating pattern
Last baseline session
values were used to
randomly allocate
animals to groups using
StatLight#11 (Yukms Co,
Ltd)
Baseline values were
used to rank animals
from low to high
performers and
pseudorandomised by
allocating to groups after
a repeated sequence
Baseline values were
used to rank animals from
low to high performers
before randomly
allocating animals to
groups by using a random
sequence generator in
Excel. Individual values
were shifted blinded from
group to group until each
group had a comparable
baseline in terms of mean
value and variation
Baseline values were used
to rank animals from low to
high performers before
randomly allocating
animals to groups by using
a random sequence
generator in Excel.
Individual values were
shifted blinded from group
to group until each group
had a comparable baseline
in terms of mean value and
variation
Last baseline session
values were used to
randomly allocate animals
to groups using a random
sequence generator in
Excel
Allocation
concealment
No allocation
concealment procedure
was followed
No allocation
concealment procedure
was followed
No allocation
concealment procedure
was followed because
only CFA animals were
injected because of the
control group being naive
animals
Syringes for model
induction were prepared
by an independent
investigator. The
investigator performing
model induction was only
aware of animal ID
No allocation
concealment procedure
was followed as the
investigator found that
colour/viscosity of CFA
solutions would have
revealed treatment
groups
Syringes for model
induction were prepared
by the investigator only
aware of the letter coded
group name. During
model induction, the
investigator was not
aware of the treatment as
animals and syringes
were picked by an
independent researcher
outside the experimental
room
Syringes for model
induction were prepared
by the investigator only
aware of the letter coded
group name. During model
induction, the investigator
was not aware of the
treatment as animals and
syringes were picked by
an independent
researcher outside the
experimental room
Syringes for model
induction were prepared by
the investigator. An
independent investigator
performing model
induction was only aware
of animal ID
(continued on next page)
2
3
5
2
R
.
W
o
d
a
rskie
t
a
l.·
1
5
7
(2
0
1
6
)2
3
5
0
–2
3
6
5
P
A
IN
®
2.4.2. Baseline performance and testing
For baseline performance and testing, animals were acclimatised
to the testing room/experimental set-up as described above.
Importantly, animals were placed into the burrowing cage alone
rather than in pairs, and allowed to burrow for 60 minutes. At the
end of the session, the weight of the displaced substrate was
measured. For this, each burrowing tube was weighed before
and after burrowing to allow for accurate measurement. In each
study, 1 to 3 baseline sessions were performed. Animals were
randomised into experimental groups according to their baseline
performance by evenly distributing “poor” and “good” burrowers
between groups; it was ensured that each experimental group
burrowed on average a similar mean amount to reduce the
impact of this source of variability on following experiments
(Table 1). Burrowing performance wasmeasured on days 1, 2, 3,
7, and 10 after CFA/sham injections.
2.5. Study design
This prospective multicentre validation study was divided into 2
parts. The first part comprised the experimental work at
participating laboratories following the basic protocol (Supple-
mental digital content 1, http://links.lww.com/PAIN/A302). All
data were centrally collected at Gru¨nenthal and then processed
for statistical analysis at H. Lundbeck A/S, who did not participate
in the experimental work or data collection.
All burrowing experiments were performed during the light
phase. The primary outcome was the change from baseline in
the amount burrowed, with a negative value representing
a decrease in burrowing behaviour. For this, the mean of the
last 2 baseline sessions was used as the baseline value. In cases
in which only one session was performed, this was used as the
baseline value. The secondary outcome was the effect of
protocol variations on burrowing behaviour. Because the study
was not designed to investigate the effect of protocol variations,
no statistical hypothesis testing has been performed for these
elements.
2.6. Statistical analysis
Details for sample size calculation are given in Table 1. The study
was powered for individual self-contained experiments at each
centre.
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Figure 1. Burrowing tube in the test cage (gravel 2-5 mm).
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For statistical analyses, we used an approach adapted from
an intention-to-treat and per-protocol analysis.22 For this, we
separately analysed 2 populations: the total population (TP),
including all animals that were allocated to treatment groups,
and the selected population (SP) population, including all
animals that were allocated to treatment groups and burrowed
over 500 g at baseline, a cutoff that has been previously
described for burrowing.62
Change from baseline was analysed using a restricted maximum
likelihood (REML)-based mixed model for repeated measures
(MMRM). Experimental group (naive, sham, CFA), time of assess-
ment (days 1, 2, 3, 7, and 10), group-by-time interaction, and
baseline burrowing-by-time interaction were used as fixed effects
for analysis of individual studies. Laboratory ID (8 participating
centres) was added as the fixed effect for combined analysis across
all studies. An unstructured covariance design was used to model
the within-animal errors (type 3 tests). A Kenward–Roger approx-
imationwas used to estimate denominator degrees of freedom. The
analysis was based on the missing-at-random assumption and
performed using all available observations. The mean differences
betweennaive andCFA, and shamandCFA,were estimatedbased
on the least squares means for the treatment-by-time interaction in
the MMRM model. The estimates are presented with P values and
95% confidence intervals (CIs). A P value ,0.05 was considered
statistically significant. Because of the exploratory nature of the
study, no adjustment for multiplicity was made. Within the text,
burrowing data are presented as mean with 95% CI.
Strain (Sprague-Dawley, Wistar [Wistar and Wistar Hannover]),
animal weight at the start of study (200-225 g, 225-250 g,.250 g),
substrate size (2-5 mm, 4-8 mm, ,1 mm [sand]), number of
training sessions (2, 3), weight of substrate provided (2000 g,
2500 g), and sex of the experimenter (female, male, mixed) were
investigated as protocol variations. As many of these factors were
given over a range,with equal values for all animalswithin a study or
laboratory, ranges have been redefined to fit a set of studies. This
could result in overlapping values but always with clear cutoff
values given by the original ranges. When applicable, the mean
values of the minimum and maximum were used as numeric
values. No statistical analyses have been performed on explana-
tory factors, and data were presented as observational findings
with descriptive statistics only.
For sample size recommendations, sample sizes for a range of
mean differences and SD were calculated. Sample size
calculations were based on a 2-sample t test informed by the
descriptive statistics and MMRM analysis for both TP and SP
populations 24 hours after CFA injections. Analyses were
performed following the exact method under a fixed scenario
adopting normal distribution, 2 sides, a nominal power of 0.8,a5
0.05, and a null hypothesis assuming no difference between
groups. For data manipulation and analysis, SAS software
Version 9.4 (SAS Institute Inc, Cary, NC, USA) was used.
3. Results
3.1. Study profile, animal characteristics, and
experimental design
Eleven studies, completed between June 2013 and September
2014, were performed at 8 different laboratories across 4 countries
(Fig. 2). Of 255 recorded animals, 249 were randomly assigned to 3
treatment groups: naive (49), sham (96), and CFA-treated (104). No
adverse events were reported across the studies, with animals
tolerating sham injections, CFA injections, and behavioural testing
well. Six animals that displayed no burrowing behaviour during
baseline sessions were excluded before group assignment. The
study protocol regarding animal exclusion was adjusted over the
course of the project, and no further animals were excluded at this
stage, as a TP and SP analysis approach was favoured instead. All
249 animals allocated to treatment groups were part of the TP
analysis, whereas 200 animals were included in the SP analysis; the
latter was defined as all rats in the TP population that burrowed at
least 500 gon average at baseline (Fig. 2). Although all eleven studies
included aCFA group, control groups varied. One study chose naive
as the control group, 4 studies chose shamas the control group, and
6 studies chose naive and sham as control groups.
Table 2
Experimental set-ups.
Substrate Cage floor Cleaning of the substrate
Boehringer Ingelheim Pharma GmbH Quartz sand Bare Autoclaved at the beginning of the study; removal of
wet clumps and faecal boli through sieving;
changed over every 6 wk
Gru¨nenthal GmbH Gravel (2-5 mm) Paper towel Every 3 mo with tap water and soap
Heidelberg University Gravel (2-3 mm) Bare Before study with tap water; faecal boli were
removed after each session
Asahi Kasei Pharma Gravel (4-8 mm) Thick paper towel Before study with tap water; faecal boli were
removed at the end of study
University of Manchester Gravel (5-8 mm) Bare After each session rinsed with tap water and faecal
boli were removed; autoclaved at the beginning and
end of the study
Eli Lilly and Company (United Kingdom)
Study 1 Gravel (5-7 mm) Thick paper towel After study with tap water
Study 2 Gravel (5-7 mm) Thick paper towel After study with tap water
Study 3 Gravel (5-7 mm) Thick paper towel After study with tap water
Imperial College London
Study 1 Gravel (2-5 mm) Paper towel After study with tap water
Study 2 Gravel (2-5 mm) Paper towel After study with tap water
Eli Lilly and company (USA) Gravel (size unspecified) Paper towel After study rinsed with tap water and diluted bleach
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All 11 studies reported randomisation procedures for group
allocation. In 4 studies, no allocation concealment was performed.
In the remaining 7 studies, allocation concealment procedures
were followed during model induction; however, because of the
occasional presence of a slight yellowish colour and the higher
viscosity of CFA suspensions, allocation concealment could be
maintained only in 2 studies. Ten studies reported that outcome
assessment was performed blinded. Oedema of the paw in some
CFA animals potentially revealed the identity of the experimental
group to the investigator in 7of these studies.
In all studies, male rats from outbred albino strains with
a starting weight range of 200 to 335 g were used (Table 3). All
CFA-injected animals received 100 mg CFA (1 mg/mL in 100 mL,
intraplantar), whereas sham animals received a saline or in-
complete Freund adjuvant injection of the same volume (Table 3).
Animals were tested at days 1, 2, 3, 7, and 10 after CFA/sham
injections with the exception of the study performed at Eli Lilly
(USA), in which animals were only tested up to 7 days. Because of
a weighing error, in study 3 at Eli Lilly (United Kingdom), only
2000 g substrate was provided.
Some variations in the features of experimental design were
permitted across studies (Fig. 3). Time for animals to acclimatise
to the test room ranged from 0 minutes to 60 minutes. Time for
acclimatisation to the experimental set-up (empty test cage)
again ranged from 0 minutes to 60 minutes. The study
performed at the University of Heidelberg introduced a 3-hour
habituation session for animals in their home cages in the
experimental room before training started. On the first training
day, another habituation session was performed in the morning,
during which animals were allowed to acclimatise to the
experimental room for 30 minutes and for a further 30 minutes
in the empty test cage. An empty test tube was then added to
Figure 2. Study profile.
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the cage, and animals spent another 60 minutes to acclimatise.
The training session was then conducted in the afternoon. As
animals were still in the behavioural room, they were allowed to
acclimatise for only 30 minutes to the experimental set-up
before an empty burrowing tube was placed in the test cage for
30 minutes. Subsequently, a filled burrowing tube was added,
and animals were allowed to burrow for 60 minutes. All
subsequent training sessions followed the standard protocol
(Fig. 3). For all training, baseline, and testing sessions, animals
were allowed to burrow for 60 minutes. The only exception was
for training sessions performed at Boehringer Ingelheim, in
which animals were allowed to burrow for 120 minutes. Across
studies, 2 to 3 training sessions and 1 to 3 baseline sessions
were performed (Fig. 3). Testing sessions followed the same
protocol as outlined for baseline sessions.
3.2. Burrowing behaviour over time
Baseline burrowing behaviour was highly variable between
individual animals and ranged from 0 to 2286 g at baseline.
Mean baseline burrowing across studies was 1113 g (95%
confidence interval: 1041-1185 g) and 1329 g (1271-1387 g) in
the TP and SP population, respectively (Supplemental digital
content 2, http://links.lww.com/PAIN/A303). To reduce the
impact of baseline variability between studies, mean change
from baseline in the amount burrowedwas chosen as the primary
outcome, with a negative value representing a decrease in
burrowing behaviour. A summary of the nonnormalised data can
be found in the supplemental material (Supplemental digital
content 2, http://links.lww.com/PAIN/A303). Statistical analysis
of individual studies showed, for both TP andSPpopulations, that
in 7 of 11 studies, burrowing behaviour was significantly
suppressed 24 hours after CFA injections as compared with
a control group (naive or sham) (Tables 4 and 5). Forty-eight
hours after CFA injections, significantly suppressed burrowing
behaviour was observed in 7 studies for the TP and in 6 studies for
the SP population. Burrowing performance over time in naive and
shamgroups from individual studies was largely within the 95%CI
of the overall mean (all animals combined of relevant group) (Fig.
4A–D). In contrast, burrowing behaviour in CFA groups wasmore
variable (Fig. 4E, F). Burrowing behaviour was comparable
between the TP and SP population, with a burrowing deficit of
Table 3
Animal and model characteristics.
Animal characteristics
Strain Sex Weight at start of
study, g
Supplier Country of origin
Boehringer Ingelheim Pharma GmbH Wistar Hannover ♂ 200-220 Charles River Germany
Gru¨nenthal GmbH Sprague-Dawley ♂ 260-310 Janvier France
Heidelberg University Wistar Hannover ♂ 250-290 Charles River Germany
Asahi Kasei Pharma Sprague-Dawley ♂ 213-247 Charles River Japan
University of Manchester Sprague-Dawley ♂ 243-335 Charles River United Kingdom
Eli Lilly and Company (United Kingdom)
Study 1 Sprague-Dawley ♂ 200-250 Charles River United Kingdom
Study 2 Wistar ♂ 200-250 Charles River United Kingdom
Study 3 Wistar ♂ 200-250 Charles River United Kingdom
Imperial College London
Study 1 Wistar ♂ 235-300 Charles River United Kingdom
Study 2 Wistar ♂ 235-300 Charles River United Kingdom
Eli Lilly and Company (USA) Sprague-Dawley ♂ 260-323 Harlan USA
Model characteristics
CFA supplier Form of CFA Concentration,
mg/mL
Volume, mL Vehicle used for
CFA solution
Boehringer Ingelheim Pharma GmbH Sigma (Germany) Liquid 1 100 NA
Gru¨nenthal GmbH DIFCO Laboratories (United Kingdom) Powder 1 100 Incomplete Freund adjuvant
Heidelberg University Sigma (Germany) Liquid 1 100 NA
Asahi Kasei Pharma Sigma (Japan) Liquid 1 100 NA
University of Manchester Sigma (United Kingdom) Liquid 1 100 NA
Eli Lilly and Company (United Kingdom)
Study 1 Sigma (United Kingdom) Liquid 1 100 NA
Study 2 Sigma (United Kingdom) Liquid 1 100 NA
Study 3 Sigma (United Kingdom) Liquid 1 100 NA
Imperial College London
Study 1 Sigma (United Kingdom) Liquid 1 100 NA
Study 2 Sigma (United Kingdom) Liquid 1 100 NA
Eli Lilly and Company (Indianapolis, USA) Sigma (St. Louis, USA) Liquid 1 100 NA
CFA, complete Freund adjuvant; NA, not applicable because CFA solution was provided in liquid form by the supplier and was injected neat; when CFA was purchased from Sigma, saline was used for sham injections.
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2374 g (2479 to 2269 g) and 2498 g (2609 to 2386 g), at 24
hours after CFA injection, respectively.
Statistical analysis of the combined data showed suppressed
burrowing peaked 24 hours after CFA injections and, although
less pronounced, was present for up to 10 days, gradually
regressing to baseline values (Fig. 5). Each of the fixed effects,
namely, group, time of assessment, laboratory ID, group-by-time
interaction, and baseline burrowing-by-time interactions, signif-
icantly contributed to heterogeneity (Table 6).
3.3. Effect of protocol variations on burrowing
behaviour—observational data
The secondary outcomewas the effect of local protocol variations
on burrowing behaviour. Because of the nature of the study
design, no statistical hypothesis testing was performed, and data
are presented as observational findings only with descriptive
statistics. Observations weremade including all animals allocated
to a treatment group (TP population), focusing on the 24-hour
time point at which burrowing deficits were most pronounced.
Data summarising burrowing behaviour at all time points by
protocol variation can be found in the supplemental material
(Supplemental digital content 3, http://links.lww.com/PAIN/
A304). There seemed to be no strain difference between Wistar
and Sprague-Dawley rats, but there was a tendency towards
a more prominent CFA-associated burrowing deficit in animals of
lower body weight. Burrowing deficits after CFA injection were
also more noticeable when a substrate of smaller size was used
(Fig. 6). An increased number of training sessions negatively
affected burrowing behaviour in naive animals. In addition, when
a larger amount of substrate was provided, the burrowing deficit
was more pronounced. The sex of the experimenter also might
have affected burrowing behaviour; increased burrowing behav-
iour was observed with a male experimenter in naive animals,
whereas in contrast, a more pronounced burrowing deficit was
present in CFA animals with a male experimenter (Supplemental
digital content 4, http://links.lww.com/PAIN/A305). It should be
noted that because the study was not designed to identify
variables that affect burrowing outcome, confounding factors
were identified, and observational data should be interpreted
cautiously. In particular, animals were unevenly distributed across
groups. An n 5 4 was recorded for the naive group that
underwent 3 training sessions and for the naive group that was
tested by a male experimenter. Furthermore, sand as the
burrowing substrate and provision of 2000 g of the substrate
was only reported by one centre in one study each.
4. Discussion
A prospective preclinical multicentre study across 8 laborato-
ries assessed the reliability of CFA-associated suppressed
burrowing in rats. Overall, reduced burrowing was partially
replicated at 6 of the 8 participating centres with an element of
variability between and within centres. The prospective multi-
centre approach was important in that it enabled the evaluation
of variability of suppressed burrowing, and it could prove
important for future studies aiming to identify the factors
underlying such variability.
We showed prominent CFA-associated suppressed burrow-
ing in 7 of 11 studies. Consistent with our results, CFA-associated
suppression of behaviour previously has been shown in feeding
behaviours,31,33,36 locomotion,21,30 and operant behaviours.18,69
Analysis of the combined data demonstrated that burrowing
deficits peaked 24 hours after CFA injection, although with high
variability between individual studies, but some studies show no
suppression of burrowing. Notably, the original sample size
calculation was based on a pilot study with a large effect size;
however, across centres, burrowing deficits ranged from 1570 to
273 g. Therefore, some studies were underpowered using the
originally estimated sample size. This could result in a reduced
Figure 3. Experimental designs across studies.
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Table 4
Time course of change from baseline in the amount burrowed of individual studies (total population).
Group N
number
24 h 48 h 72 h 7 d 10 d
Boehringer Ingelheim Pharma
GmbH
Naive 9 238 (2269 to 193), P 5 0.0002 86 (2132 to 304), P 5 0.006 291 (2320 to 138), P 5 0.2 85 (291 to 261), P 5 0.002 216 (2179 to 147), P 5 0.2
Sham 10 260 (2280 to 160), P 5 0.0002 239 (2245 to 167), P 5 0.04 20 (2198 to 238), P 5 0.046 37 (2130 to 204), P 5 0.005 122 (231 to 275), P 5 0.02
CFA 10 2740 (2960 to 2520) 2369 (2575 to 2163) 2308 (2526 to 290) 2331 (2498 to 2164) 2151 (2306 to 4)
Gru¨nenthal GmbH Naive 7 49 (2163 to 261), P < 0.0001 227 (218 to 472), P 5 0.008 70 (2308 to 448), P 5 0.02 354 (185 to 523), P 5 0.08 112 (2126 to 314), P 5 0.5
Sham 7 84 (2126 to 294), P < 0.0001 56 (2187 to 299), P 5 0.06 227 (2403 to 349), P 5 0.04 207 (40 to 374), P 5 0.5 203 (215 to 421), P 5 1.0
CFA 7 2898 (21110 to 2686) 2307 (2552 to 262) 2631 (21009 to 2253) 126 (243 to 295) 205 (215 to 425)
Heidelberg University Naive 8 196 (2161 to 553), P 5 0.3 172 (2163 to 507), P 5 0.7 376 (70 to 682), P 5 0.9 297, (30 to 564), P 5 0.4 337 (241 to 715), P 5 0.7
CFA 8 298 (2455 to 259) 282 (253 to 617) 338 (32 to 644) 461 (194 to 728) 246 (2132 to 624)
Asahi Kasei Pharma Sham 12 256 (277 to 589), P 5 0.006 237 (2102 to 576), P 5 0.03 235 (2106 to 576), P 5 0.02 328 (270 to 726), P 5 0.4 112 (2260 to 484), P 5 1.0
CFA 12 2488 (2821 to 2155) 2337 (2676 to 2) 2408 (2749 to 267) 58 (2328 to 444) 120 (2241 to 481)
University of Manchester Naive 8 15 (2342 to 372), P 5 0.03 207 (2212 to 626), P 5 0.08 271 (2199 to 741), P 5 0.2 510 (85 to 935), P 5 0.2 282 (2226 to 790), P 5 0.4
Sham 8 470 (113 to 827), P 5 0.06 728 (309 to 1147), P 5 0.01 482 (12 to 952), P 5 0.9 991 (566 to 1416), P 5 0.4 650 (142 to 1158), P 5 0.6
CFA 8 392 (35 to 749) 244 (2175 to 663) 542 (72 to 1012) 200 (2225 to 625) 0 (2508 to 508)
Eli Lilly and Company (United Kingdom)
Study 1 Naive 9 2305 (2813 to 203), P 5 0.03 2386 (2627 to 2145), P 5 0.08 22 (2431 to 427), P 5 0.2 216 (2209 to 641), P 5 0.2 2114 (2678 to 450), P 5 0.4
Sham 9 2400 (2700 to 2100), P 5 0.06 2203 (2452 to 46), P 5 0.01 2331 (2760 to 98), P 5 0.9 2520 (2945 to 295), P 5 0.4 2247 (2811 to 317), P 5 0.6
CFA 9 2833 (21133 to 2533) 2707 (2948 to 2466) 2380 (2809 to 49) 2236 (2661 to 189) 2446 (21010 to 118)
Study 2 Sham 16 187 (7 to 367), P 5 0.04 197 (230 to 424), P 5 0.1 171 (282 to 424), P 5 0.8 291 (70 to 512), P 5 0.7 162 (289 to 413), P 5 0.7
CFA 16 299 (2279 to 81) 256 (2283 to 171) 119 (2134 to 372) 351 (130 to 572) 241 (210 to 492)
Study 3 Sham 16 261 (272 to 594), P 5 0.06 403 (125 to 681), P 5 0.045 192 (2143 to 527), P 5 0.8 340 (3 to 677), P 5 0.4 230 (289 to 549), P 5 0.3
CFA 16 2203 (2526 to 120) 217 (2295 to 261) 139 (2196 to 474) 139 (2198 to 476) 239 (2358 to 280)
Imperial College London
Study 1 Naive 4 721 (235 to 1207), P 5 0.002 221 (2312 to 754), P 5 0.6 390 (2223 to 1003), P 5 0.9 280 (2782 to 622), P 5 0.8 2267 (21047 to 513), P 5 0.6
Sham 4 2178 (2664 to 308), P 5 0.09 133 (2400 to 666), P 5 0.8 288 (2325 to 901), P 5 0.7 310 (2392 to 1012), P 5 0.7 414 (2366 to 1194), P 5 0.1
CFA 4 2849 (21335 to 2363) 34 (2499 to 567) 438 (2177 to 1053) 72 (2630 to 774) 2560 (21342 to 222)
Study 2 Naive 4 2670 (21189 to 2151), P 5 0.9 2183 (2681 to 315), P 5 0.07 16 (2619 to 651), P 5 0.1 327 (2347 to 1001), P 5 0.3 2522 (21177 to 133), P 5 0.9
Sham 4 286 (2607 to 435), P 5 0.1 117 (2383 to 617), P 5 0.02 2135 (2772 to 502), P 5 0.2 119 (2557 to 795), P 5 0.5 177 (2478 to 832), P 5 0.1
CFA 4 2736 (21253 to 2219) 2956 (21452 to 2460) 2847 (21475 to 2216) 2186 (2856 to 484) 2581 (21232 to 70)
Eli Lilly and Company (USA) Sham 10 48 (2164 to 260), P 5 0.0001 46 (2109 to 201), P 5 0.005 226 (8 to 444), P 5 0.3 12 (2186 to 210), P 5 0.4 —
CFA 10 2742 (2954 to 2530) 2335 (2490 to 2180) 37 (2181 to 255) 2127 (2325 to 71) —
% of naive vs CFA comparisons reporting significant
suppression of burrowing
71 29 14 14 0
% of sham vs CFA comparisons reporting significant
suppression of burrowing
60 80 30 10 10
Data shown as mean (95% confidence interval) and analysed using a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM) approach with fixed effects (group [naive, sham, CFA]), time of assessment (days 1, 2, 3, 7, 100), group-by-time, and baseline burrowing-by-time
interactions). P values given for naive and sham groups refer to comparison with the complete Freund adjuvant (CFA) group. Significance level has been set at P , 0.05, bold values indicate significant differences to the CFA treated groups.
CFA, complete Freund adjuvant.
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Table 5
Time course of change from baseline in the amount burrowed of individual studies (selected population).
Group N
number
24 h 48 h 72 h 7 d 10 d
Boehringer Ingelheim Pharma GmbH Naive 9 238 (2269 to 193), P5 0.0002 86 (2132 to 304), P 5 0.006 291 (2320 to 138), P 5 0.2 85 (291 to 261), P 5 0.002 216 (2179 to 147), P 5 0.2
Sham 10 260 (2280 to 160), P5 0.0002 239 (2245 to 167), P 5 0.04 20 (2198 to 238), P 5 0.046 37 (2130 to 204), P 5 0.005 122 (231 to 275), P 5 0.02
CFA 10 2740 (2960 to 2520) 2369 (2575 to 2163) 2308 (2526 to 290) 2331 (2498 to 2164) 2151 (2306 to 4)
Gru¨nenthal GmbH Naive 7 49 (2163 to 261), P < 0.0001 227 (218 to 472), P 5 0.008 70 (2308 to 448), P 5 0.02 354 (185 to 523), P 5 0.08 112 (2126 to 314), P 5 0.5
Sham 7 84 (2126 to 294), P < 0.0001 56 (2187 to 299), P 5 0.06 227 (2403 to 349), P5 0.04 207 (40 to 374), P 5 0.5 203 (215 to 421), P 5 1.0
CFA 7 2898 (21110 to 2686) 2307 (2552 to 262) 2631 (21009 to 2253) 126 (243 to 295) 205 (215 to 425)
Heidelberg University Naive 6 303 (2142 to 748), P 5 0.2 265 (2162 to 692), P 5 0.8 554 (197 to 911), P 5 0.5 472 (225 to 719), P 5 0.8 297 (2160 to 754), P 5 09
CFA 7 2106 (2518 to 306) 345 (251 to 741) 383 (52 to 714) 433 (206 to 660) 274 (2149 to 697)
Asahi Kasei Pharma Sham 7 287 (2524 to 350), P 5 0.04 268 (2493 to 357), P 5 0.1 278 (2507 to 351), P5 0.04 140 (2356 to 636), P 5 0.2 242 (2605 to 521), P 5 0.8
CFA 6 2881 (21355 to 2407) 2632 (21093 to 2171) 2864 (21329 to 2399) 2439 (2976 to 98) 54 (2556 to 664)
University of Manchester Naive 6 119 (2179 to 417), P 5 0.2 399 (11 to 787), P 5 0.9 479 (38 to 920), P 5 0.6 481 (5 to 957), P 5 0.5 187 (2411 to 785), P 5 0.7
Sham 6 580 (282 to 878), P 5 0.4 838 (450 to 1226), P 5 0.1 726 (285 to 1167), P 5 0.2 857 (381 to 1333), P 5 0.1 716 (116 to 1316), P 5 0.1
CFA 6 385 (87 to 683) 379 (27 to 765) 324 (2117 to 765) 243 (2233 to 719) 211 (2609 to 587)
Eli Lilly and Company1 (United Kingdom)
Study 1 Naive 8 2302 (2661 to 57), P 5 0.02 2361 (2161 to2106), P5 0.04 27 (2521 to 507), P 5 0.3 69 (2433 to 571), P 5 0.3 2367 (21012 to 278), P5 0.8
Sham 7 2499 (2862 to2136), P5 0.1 2232 (2518 to 54), P 5 0.01 2357 (2902 to 188), P5 0.9 2579 (21112 to246), P5 0.5 2220 (2904 to 464), P 5 0.6
CFA 7 2958 (21321 to 2595) 2798 (21068 to 2528) 2401 (2944 to 142) 2308 (2841 to 225) 2506 (21188 to 176)
Study 2 Sham 8 15 (2248 to 278), P 5 0.2 49 (2243 to 341), P 5 0.08 250 (2358 to 258), P 5 0.5 105 (2179 to 389), P 5 0.9 233 (2335 to 269), P 5 0.9
CFA 10 2259 (2494 to 224) 2322 (2583 to 261) 2216 (2490 to 58) 69 (2184 to 322) 219 (2288 to 250)
Study 3 Sham 12 266 (2108 to 640), P 5 0.03 404 (102 to 706), P 5 0.02 312 (223 to 647), P 5 0.1 214 (2162 to 590), P 5 0.5 195 (2205 to 595), P 5 0.4
CFA 13 2351 (2698 to 24) 2135 (2425 to 155) 296 (2419 to 227) 30 (2333 to 393) 251 (2435 to 333)
Imperial College London
Study 1 Naive 4 660 (107 to 1213), P 5 0.008 229 (2283 to 741), P 5 0.9 316 (2111 to 743), P 5 0.5 2117 (2701 to 467), P 5 0.5 2258 (2766 to 250), P 5 0.6
Sham 3 2162 (2815 to 491), P 5 0.1 2114 (2720 to 492), P 5 0.5 2246 (2752 to 260), P 5
0.07
2184 (2874 to 506), P 5 0.4 2140 (2973 to 693), P 5 0.5
CFA 3 2985 (21614 to 2356) 190 (2392 to 772) 552 (66 to 1038) 230 (2432 to 892) 2564 (21366 to 238)
Study 2 Naive 4 2674 (21186 to 2162), P 5
0.8
2193 (2640 to 254), P 5 0.05 210 (2622 to 602), P5 0.09 272 (2445 to 989), P 5 0.4 2543 (21237 to 151), P5 0.9
Sham 3 63 (2531 to 657), P 5 0.08 317 (2200 to 834), P 5 0.009 49 (2661 to 759), P 5 0.09 70 (2761 to 901), P 5 0.6 118 (2686 to 922), P 5 0.2
CFA 4 2752 (21266 to 2238) 2952 (21401 to 2503) 2891 (21504 to 2278) 2241 (2960 to 478) 2598 (21294 to 98)
Eli Lilly and Company (USA) Sham 10 48 (2164 to 260), P 5 0.0001 46 (2109 to 201), P 5 0.005 226 (8 to 444), P 5 0.3 12 (2186 to 210), P 5 0.4 —
CFA 10 2742 (2954 to 2530) 2335 (2490 to 2180) 37 (2181 to 255) 2127 (2325 to 71) —
% of naive vs CFA comparisons reporting
significant suppression of burrowing
— — 57 42 14 14 0
% of sham vs CFA comparisons reporting
significant suppression of burrowing
— — 50 50 30 10 10
Data shown as mean (95% confidence interval) and analysed using a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM) approach with fixed effects {group (naive, sham, complete Freund adjuvant [CFA]), time of assessment (days 1, 2, 3, 7, 10), group-by-time and
baseline burrowing-by-time interactions}. P values given for naive and sham groups refer to comparison to the CFA group. Significance level has been set at P , 0.05, bold values indicate significant differences to the CFA treated groups.
CFA, complete Freund adjuvant.
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chance to detect a true effect. We have calculated sample size
recommendations for a range of mean differences and SD
(Supplemental digital content 5, http://links.lww.com/PAIN/
A306) to provide guidance for future studies. Increasing the
sample size of underpowered studies would result in a more
accurate estimated effect size and could reduce variability within
studies. Group allocation, time of assessment, laboratory ID,
group-by-time interaction, and baseline burrowing-by-time in-
teraction all significantly contributed to the heterogeneity across
studies. Adjustment for laboratory ID showed a change from
baseline similar to data without adjustment, demonstrating that
suppression of burrowing is robust across laboratories, despite
the variability in the effect size.
We also observed effects of local protocol variations on
burrowing behaviour. No statistical analyses were performed on
these observations, as the study was not designed to formally
detect such effects. Confounding factors such as uneven
distribution of animals across groups and variables reported only
by one centre should be considered when interpreting the data.
Observations made were reported both for transparency and to
identify variability factors in burrowing behaviour meriting future
study. Although strain differences have been reported for other
Figure 4.Burrowing behaviour in individual studies—mean change from the baseline amount burrowed. (A, C, E) Total population (n5 249): burrowing behaviour
in individual studies in naive (A), sham (C), and complete Freund adjuvant (CFA) (E) groups. Gray area represents the mean with 95% confidence interval (CI).
(B, D, F) Selected population (n5 200): burrowing behaviour in individual studies in naive (B), sham (D), and CFA (F) groups. Gray area represents the mean
with 95% CI.
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outcome measures,8,42,63 in this study, no strain differences
between Sprague-Dawley and Wistar rats were observed for
suppressed burrowing. Animals with a lower body weight
developed an increased burrowing deficit, whereas burrowing
in sham or naive groups was unaffected. As all animals received
the same volume and concentration of CFA, it may be that smaller
animals received relatively more CFA per paw mass, resulting in
a more severe inflammatory response leading to a larger
burrowing deficit. The suppression of burrowing observed with
a smaller amount of provided substrate is most likely due to the
reduced amount of substrate available. In naive animals, we
observed an increased burrowing deficit withmale experimenters
as compared with female experimenters or mixed experimenter
teams. Because a male experimenter was only reported by one
centre and only 4 rats were in this group, this result may be due to
chance or a centre-specific effect. A study in mice showed that
the experimenter’s sex affects pain outcomemeasures inmice.67
Further studies are required to verify whether burrowing
behaviour in rats is also affected by the experimenter’s sex.
Additional studies would be required to assess the impact of the
substrate size and number of training sessions on burrowing,
specifically whether a small sized substrate is superior to larger
sized substrate and whether an increased number of training
sessions reduces burrowing behaviour.
To assess the effect of excluding “poor” burrowers, we
analysed the TP (all animals allocated to treatment groups) and
an SP (all allocated animals that burrowed above 500 g at
baseline), an approach adapted from the intention-to-treat and
per-protocol analyses used in clinical trials.22 In both populations,
the pattern of suppressed burrowing was comparable, which
suggests that suppressed burrowing is a robust measure.
Therefore, we recommend not to exclude “poor” burrowers.
Excluding animals would increase variability, resulting in a less
accurate effect size estimates. Exclusions could also result in
attrition bias, an issue particularly important for studies using
relatively small sample sizes.1,13,24
Adding nonevoked ethologically relevant outcome measures
to assess the global impact of pain previously has been
suggested as a potential means to improve translation.49,56,68,75
Development and validation of these measures is of key
relevance, particularly as spontaneous pain, functioning, and
quality of life are primary outcome measures in clinical trials.
Suppression of burrowing reflects the global impact of purport-
edly pain-induced reduction of general “well-being”.27–29,74
Although suppressed burrowing is not a pain-specific test,
treatment with known analgesics has been shown to attenuate
decreased burrowing behaviour in various pain models,
suggesting a pain-specific component.2,9,35,61,62 A limitation
of our study was the lack of an independent validation of
suppressed burrowing as indicative of a pain-specific outcome
measure; it will be crucial to address the interdependence of this
connection in future studies. Correlation with other nonevoked
Figure 5. Time course of change from baseline in the amount burrowed. (A) Total population (n5 249). (B) Selected population (n5 200). Data shown as mean
with 95% confidence interval (CI) and analysed using a restricted maximum likelihood (REML)-based mixedmodel for repeated measures (MMRM) approach with
fixed effects {group (naive, sham, complete Freund adjuvant [CFA]), time of assessment (days 1, 2, 3, 7, 10), laboratory ID, group-by-time, and baseline burrowing-
by-time interactions}. *Significant difference between the naive and CFA groups. #Significant difference between the sham and CFA group. */# P , 0.05.
Table 6
Type 3 tests of fixed effects.
Fixed effect Total population Selected population
Nominator, df Denominator, df F Pr > F Denominator, df F Pr > F
Experimental group (naive, sham, CFA) 2 239 13.44 ,0.0001* 190 16.85 ,0.0001*
Time of assessment (days 1, 2, 3, 7, 10) 4 238 5.75 0.0002* 189 2.49 0.0444*
Laboratory ID (8 participating centres) 7 239 4.74 ,0.0001* 189 7.68 ,0.0001*
Group-by-time interaction 8 340 3.59 0.0005* 270 4.24 ,0.0001*
Baseline burrowing-by-time interaction 5 249 14.50 ,0.0001* 193 10.34 ,0.0001*
Data were analysed using a restricted maximum likelihood (REML)-based mixed model for repeated measures (MMRM).
* Significant difference between variables within fixed effect.
CFA, complete Freund adjuvant; df, degrees of freedom; Pr, probability.
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pain-related outcomes would be essential, particularly as a lack
of correlation has been shown between burrowing performance
and evoked mechanosensory thresholds in a neuropathic pain
rat model,35 which suggests that suppressed burrowing may
reflect a pain component not directly linked to sensory gain.
Furthermore, pharmacological validation studies should be con-
ducted, preferably informed by robust meta-analyses of clinical
trials to guide both drug and dose selection.17,53 First, it should be
demonstrated to what extent clinically efficacious drugs reverse
suppression of burrowing. In the CFA model, ibuprofen has been
shown to reverse suppressedburrowing,whereasgabapentin,which
has a large body of evidence supporting efficacy in neuropathic, but
not inflammatory, pain, is appropriately inefficacious,2,20,62 suggest-
ing good pharmacologic sensitivity of suppressed burrowing.
Figure 6. Burrowing performance 24 hours after complete Freund adjuvant (CFA) injections in subgroups factoring in protocol variations (total population). (A)
Burrowing dependent on strain. (B) Burrowing dependent on the weight of animals at the start of study. (C) Burrowing dependent on the substrate size. Data
shown as single values (diamonds) and mean (square) with 95% confidence interval (whiskers).
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Second, compounds such as neurokinin 1 antagonists and
cannabinoid 2 receptor agonists that have been shown to be
efficacious in animal pain models measuring evoked endpoints
but have failed in clinical trials48,65,75 should be tested to assess
the degree of pain specificity of burrowing.
We chose the CFA model, as we expected a high likelihood of
ongoing spontaneous pain.19,46,47 To validate suppressed
burrowing as a pain-relevant outcomemeasure for neuropathic
pain conditions, burrowing behaviour should be measured in
a range of models. An important aspect of modelling
neuropathic pain is gender generalizability. Animal studies
use mainly male rodents, whereas clinical trials enrol both
sexes.7 Importantly, sex differences in behavioural responses
have been shown in rodents.15,42,66 As the primary interest of
our study was to evaluate burrowing across centres and not
establish the model’s predictive validity as a pain outcome
measure, only male rats were used. However, future validation
studies should include female rats.
A multicentre approach for preclinical studies is very novel.
Similar to clinical multicentre trials, the study design should be
of a high standard, and results should be reported trans-
parently. In this study, all participating centres followed
a basic protocol that was previously reviewed and agreed
upon by all parties; however, minor changes were permitted to
pragmatically accommodate for local variations in laboratory
practice and procedures. No detailed specifications were
given regarding the scope of these changes, inevitably
resulting in some degree of uncontrolled heterogeneity
between studies. An external review of the protocol could
have identified this issue before study start. Variations were
also reported concerning bias reduction procedures. Al-
though guidance on Good Laboratory Practice was given,
there was variability between centres as to the extent to which
such practice was followed, most notably as a result of
constraints imposed by established local procedures. Future
preclinical multicentre studies should not only provide Good
Laboratory Practice training and validation but also establish
an independent central monitor, similar to phase III clinical
trials, to ensure protocol compliance and bias reduction.6 It
should be noted that despite following bias reduction
procedures, because of CFA-induced paw oedema, alloca-
tion concealment and blinding could not be maintained in all
studies, potentially resulting in an overestimation of the effect
size.12,13,64 As it was not possible to control for all model-
specific factors, it is crucial to report data as transparently as
possible to clearly highlight study limitations related to internal
validity issues. In clinical trials, the near-universal implementa-
tion of the CONSORT reporting guidelines has noticeably
improved reporting rigour and transparency.70 Although AR-
RIVE guidelines32,43 and other recommendations34,55,69 pro-
vide a similar framework for preclinical studies, they are not yet
as well established as CONSORT4,32; however, a similar
positive impact on preclinical studies is expected as these
guidelines achieve broader acceptance and implementation. In
this study, we reported according to ARRIVE guidelines and
presented the data as transparently as possible. Recommen-
dations for future studies, based on our practical experience,
are summarised in Table 7. An audio abstract of this study is
available in the supplemental material (Supplemental digital
content 7, Audio, http://links.lww.com/PAIN/A310.)
In conclusion, our approach demonstrates how implemen-
tation of a multicentre study design to evaluate novel preclinical
outcome measures can yield robust data and can help
accelerate the validation of outcome measures, pain models,
and pharmacological interventions. This hopefully may help
inform the design and conduct of similar future multicentre
studies.
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Table 7
Recommendations for future multicentre animal studies.
Recommendation
Study design
Appoint study manager
Protocol development and refinement: each participating centre has to agree on
protocol
External review might be beneficial to identify problems
Required training (inclusive Good Laboratory Practice) should be identified
and provided at this stage
Plan for statistical analysis should be agreed upon in the protocol—changes
to the analysis should be reported and explained
Independent protocol registration might be beneficial to ensure compliance
during experimental phase
Experimental phase
Centralised administration: centralised coordination and monitoring, Web-based
data entry portal, randomisation process
Enables easier monitoring and quality assurance
Proactive site monitoring and audit through central administration could be
beneficial to identify problems during the experimental phase
Reporting
Transparent reporting such as ARRIVE guidelines—it may be that some
adaptation of these guidelines is required to assist reporting of preclinical
multicentre studies
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